Cargando…
Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial
OBJECTIVE: Evaluate the efficacy of AYUSH 64, a standard polyherbal Ayurvedic drug in COVID-19. METHODS: During the first pandemic wave, 140 consenting and eligible hospitalized adult participants with mild-moderate symptomatic disease (specific standard RT-PCR assay positive) were selected as per a...
Autores principales: | Chopra, Arvind, Tillu, Girish, Chuadhary, Kuldeep, Reddy, Govind, Srivastava, Alok, Lakdawala, Muffazal, Gode, Dilip, Reddy, Himanshu, Tamboli, Sanjay, Saluja, Manjit, Sarmukaddam, Sanjeev, Gundeti, Manohar, Raut, Ashwini Kumar, Rao, B. C. S., Yadav, Babita, Srikanth, Narayanam, Patwardhan, Bhushan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019690/ https://www.ncbi.nlm.nih.gov/pubmed/36928877 http://dx.doi.org/10.1371/journal.pone.0282688 |
Ejemplares similares
-
Universal Health Coverage and AYUSH systems
por: Patwardhan, Bhushan, et al.
Publicado: (2018) -
AYUSH for COVID-19 management
por: Tillu, Girish, et al.
Publicado: (2020) -
Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol
por: Chopra, Arvind, et al.
Publicado: (2022) -
Corrigendum: Randomized, Double Blind, Placebo Controlled, Clinical Trial to Study Ashwagandha Administration in Participants Vaccinated Against COVID-19 on Safety, Immunogenicity, and Protection With COVID-19 Vaccine–A Study Protocol
por: Chopra, Arvind, et al.
Publicado: (2022) -
AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial
por: Reddy, R. Govind, et al.
Publicado: (2020)